ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • Next Page »
Search Again »
  • Abstract Number: 0941 • ACR Convergence 2021

    Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA

    Timothy Seo1, Vishal Deshmukh1 and Yusuf Yazici2, 1Biosplice Therapeutics, Inc., San Diego, CA, 2New York University School of Medicine, La Jolla, CA

    Background/Purpose: Osteoarthritis (OA) is characterized by increased cartilage thinning, bone remodeling, and inflammation. Post-traumatic OA, which develops after acute direct trauma to the joints, accounts…
  • Abstract Number: 1469 • ACR Convergence 2021

    Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

    Timothy Seo1, Vishal Deshmukh1 and Yusuf Yazici2, 1Biosplice Therapeutics, Inc., San Diego, CA, 2New York University School of Medicine, La Jolla, CA

    Background/Purpose: Meniscal injuries are the most common pathology of the knee and are associated with pain, stiffness, and localized swelling. Meniscal damage is a frequent…
  • Abstract Number: 891 • 2019 ACR/ARP Annual Meeting

    Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

    Vishal Deshmukh1, Alyssa O'Green 1, Carine Bossard 1, Tim Seo 1, Lisa Lamangan 1, Maureen Ibanez 1, Abdullah Ghias 1, Carolyn Lai 1, Long Do 1, Shawn Cho 1, Joseph Cahiwat 1, Kevin Chiu 1, Melinda Pedraza 1 and Yusuf Yazici 1, 1Samumed, LLC, San Diego, CA

    Background/Purpose: In the synovial joint, Wnt pathway upregulation contributes to osteoarthritis (OA) by increasing osteocyte differentiation, cartilage thinning, and inflammation. Lorecivivint (LOR; SM04690), a novel…
  • Abstract Number: 1308 • 2019 ACR/ARP Annual Meeting

    Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

    Sarah Kennedy 1, Chris Swearingen 1, Jeyanesh Tambiah1, Daniel Clauw 2 and Philip G Conaghan 3, 1Samumed, LLC, San Diego, 2Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: Patient-reported outcomes (PROs) in knee osteoarthritis (OA) trials have been difficult to accurately measure due to heterogenous sources of pain (e.g., from comorbid conditions…
  • Abstract Number: 1326 • 2019 ACR/ARP Annual Meeting

    Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

    Ismail Simsek 1, Chris Swearingen 1, Sarah Kennedy 1, Jeyanesh Tambiah 1, Yusuf Yazici2, Nancy Lane 3 and Marc C. Hochberg 4, 1Samumed, LLC, San Diego, 2Samumed, LLC, San Diego, CA, 3University of California at Davis Medical Center, Sacramento, CA, 4University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Recent concerns over osteoarthritis (OA) pharmacotherapy safety have led to revision of treatment guidelines and highlight the need for therapies with good safety profiles.…
  • Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting

    The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

    Yusuf Yazici1, Sarah Kennedy 2, Chris Swearingen 2 and Jeyanesh Tambiah 2, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC, San Diego

    Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
  • Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

    Yusuf Yazici1, Timothy E. McAlindon2, Allan Gibofsky3, Nancy Lane4, Christian Lattermann5, Nebojsa Skrepnik6, Christopher Swearingen1, Anita DiFrancesco1, Jeymi Tambiah1 and Marc Hochberg7, 1Samumed, LLC, San Diego, CA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, 4Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Tucson Orthopaedic Institute, Tucson, AZ, 7University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…
  • Abstract Number: 1364 • 2018 ACR/ARHP Annual Meeting

    Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

    Jeyanesh Tambiah1, Sarah Kennedy1, Heli Ghandehari1, Christopher Swearingen1 and Marc C. Hochberg2, 1Samumed, LLC, San Diego, CA, 2University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional limitation, and physical disability due to articular cartilage degradation and bone remodeling. Wnt signaling is involved…
  • Abstract Number: 1366 • 2018 ACR/ARHP Annual Meeting

    Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis

    Vibeke Strand1, Heli Ghandehari2, Christopher Swearingen2 and Jeyanesh Tambiah2, 1Stanford University School of Medicine, Palo Alto, CA, 2Samumed, LLC, San Diego, CA

    Background/Purpose: SM04690, a small molecule, intra-articular (IA) Wnt pathway inhibitor, is in development for knee OA treatment. A phase 2, 52-week, trial evaluated changes in…
  • Abstract Number: 935 • 2017 ACR/ARHP Annual Meeting

    Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

    Yusuf Yazici1, Timothy E. McAlindon2, Allan Gibofsky3, Nancy E. Lane4, Daniel J. Clauw5, Eddie Armas6, Nebojsa Skrepnik7, Christopher J. Swearingen1, Anita DiFrancesco1, Jeymi Tambiah1 and Marc Hochberg8, 1Samumed, LLC, San Diego, CA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, 4Center for Musculoskeletal Health, University of California at Davis, Hillsborough, CA, 5Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, 6Well Pharma Medical Research, Miami, FL, 7Tuscon Orthopedics Institute, Tuscon, AZ, 8Head, Division of Rheumatology & Clinical Immunology; Vice Chair, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, disability and joint deformity due to articular cartilage degradation and bone remodeling. Wnt signaling is involved in…
  • Abstract Number: 1201 • 2017 ACR/ARHP Annual Meeting

    Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis

    Philip G. Conaghan1, Anita DiFrancesco2, Christopher J. Swearingen2, Sarah Kennedy2, Ismail Simsek2, Jeymi Tambiah2 and Yusuf Yazici2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Samumed, LLC, San Diego, CA

    Background/Purpose: Kellgren-Lawrence [KL] radiographic grading is used to classify knee osteoarthritis (OA), but may not accurately reflect disease progression. Classifying subjects by baseline medial joint…
  • Abstract Number: 1204 • 2017 ACR/ARHP Annual Meeting

    Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

    Yusuf Yazici1, Timothy E. McAlindon2, Allan Gibofsky3, Nancy E. Lane4, Nebojsa Skrepnik5, Eddie Armas6, Christopher J. Swearingen1, Anita DiFrancesco1, Jeymi Tambiah1 and Marc Hochberg7, 1Samumed, LLC, San Diego, CA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, 4Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, 5Tuscon Orthopedics Institute, Tuscon, AZ, 6Well Pharma Medical Research, Miami, FL, 7Head, Division of Rheumatology & Clinical Immunology; Vice Chair, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, disability and joint deformity due to articular cartilage degradation and bone remodeling. Wnt signaling is involved in…
  • Abstract Number: 2120 • 2016 ACR/ARHP Annual Meeting

    Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Treatment for Degenerative Disc Disease

    Charlene Barroga1, Vishal Deshmukh1, Luis Dellamary1, Josh Stewart1, Haide Hu2, John Hood2 and Yusuf Yazici1, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC (formerly), San Diego, CA

    Background/Purpose: Degenerative Disc Disease (DDD), one of the main causes of low back pain, is characterized by degeneration of intervertebral disc, nucleus pulposus (NP), and…
  • Abstract Number: 2143 • 2016 ACR/ARHP Annual Meeting

    A Small Molecule, SM04690, Has Inhibitory Effects on the Wnt Pathway and Inflammation in Vitro, with Potential Implications for the Treatment of Osteoarthritis

    Vishal Deshmukh1, Maureen Ibanez1, Charlene Barroga1, John Hood2 and Yusuf Yazici1, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC (formerly), San Diego, CA

    Background/Purpose:   Osteoarthritis (OA) involves thinning cartilage and increased subchondral bone. Amongst many cellular processes, inflammation has been associated with OA. Wnt signaling plays a…
  • Abstract Number: 2350 • 2016 ACR/ARHP Annual Meeting

    Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

    Christopher J. Swearingen1, Sharmila Majumdar2, Ismail Simsek1, Anita DiFrancesco1, Jeymi Tambiah1 and Yusuf Yazici1, 1Samumed, LLC, San Diego, CA, 2University of California San Francisco, San Francisco, CA

    Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional impairment, disability, and joint space narrowing due to degradation of articular cartilage and bone remodeling. The…
  • 1
  • 2
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology